Open AccessThe need for a population-based, dose optimization study for recombinant tissue plasminogen activator in acute ischemic stroke: A study from a tertiary care teaching hospital from South India
Author(s) -
Siju V Abraham,
Fazil Thaha,
S Vimal Krishnan,
Athulya Shajan,
Jayaraj Mymbilly Balakrishnan,
Babu Urumese Palatty
Publication year - 2017
Publication title -
annals of indian academy of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 31
eISSN - 1998-3549
pISSN - 0972-2327
DOI - 10.4103/0972-2327.199911
Subject(s) - medicine , wilcoxon signed rank test , mann–whitney u test , tissue plasminogen activator , population , tertiary care , observational study , stroke (engine) , guideline , population study , recombinant tissue plasminogen activator , acute stroke , ischemic stroke , modified rankin scale , pathology , ischemia , mechanical engineering , environmental health , engineering
The guideline recommended dose of intravenous (i.v) recombinant tissue-type plasminogen activator (rt-PA) for acute ischemic stroke is 0.9 mg/kg in the European and American populations. In Asiatic population, some studies have shown that a lower dose of i.v rt-PA is equally efficacious.